|
Gene: ESCO1 |
Gene summary for ESCO1 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ESCO1 | Gene ID | 114799 |
Gene name | establishment of sister chromatid cohesion N-acetyltransferase 1 | |
Gene Alias | A930014I12Rik | |
Cytomap | 18q11.2 | |
Gene Type | protein-coding | GO ID | GO:0000819 | UniProtAcc | A0A024RC19 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
114799 | ESCO1 | SYSMH3 | Human | Oral cavity | OSCC | 4.72e-15 | 4.79e-01 | 0.2442 |
114799 | ESCO1 | SYSMH6 | Human | Oral cavity | OSCC | 1.50e-06 | 1.98e-01 | 0.1275 |
114799 | ESCO1 | P1_S1_AK | Human | Skin | AK | 2.02e-02 | 2.50e-01 | -0.3399 |
114799 | ESCO1 | P4_S8_cSCC | Human | Skin | cSCC | 3.44e-06 | 2.35e-01 | -0.3095 |
114799 | ESCO1 | P5_S10_cSCC | Human | Skin | cSCC | 4.55e-06 | 1.67e-01 | -0.299 |
114799 | ESCO1 | P1_cSCC | Human | Skin | cSCC | 1.10e-15 | 5.95e-01 | 0.0292 |
114799 | ESCO1 | P2_cSCC | Human | Skin | cSCC | 7.76e-05 | 2.47e-01 | -0.024 |
114799 | ESCO1 | P4_cSCC | Human | Skin | cSCC | 2.63e-08 | 2.98e-01 | -0.00290000000000005 |
114799 | ESCO1 | P10_cSCC | Human | Skin | cSCC | 2.33e-12 | 4.86e-01 | 0.1017 |
114799 | ESCO1 | male-WTA | Human | Thyroid | PTC | 1.17e-16 | 1.41e-01 | 0.1037 |
114799 | ESCO1 | PTC01 | Human | Thyroid | PTC | 3.42e-13 | 2.64e-01 | 0.1899 |
114799 | ESCO1 | PTC03 | Human | Thyroid | PTC | 2.80e-07 | 2.83e-01 | 0.1784 |
114799 | ESCO1 | PTC04 | Human | Thyroid | PTC | 9.43e-18 | 3.67e-01 | 0.1927 |
114799 | ESCO1 | PTC05 | Human | Thyroid | PTC | 5.69e-17 | 6.43e-01 | 0.2065 |
114799 | ESCO1 | PTC06 | Human | Thyroid | PTC | 2.45e-29 | 6.21e-01 | 0.2057 |
114799 | ESCO1 | PTC07 | Human | Thyroid | PTC | 2.80e-43 | 6.77e-01 | 0.2044 |
114799 | ESCO1 | ATC09 | Human | Thyroid | ATC | 4.68e-06 | 2.13e-01 | 0.2871 |
114799 | ESCO1 | ATC12 | Human | Thyroid | ATC | 4.20e-06 | 1.15e-01 | 0.34 |
114799 | ESCO1 | ATC13 | Human | Thyroid | ATC | 6.17e-29 | 5.57e-01 | 0.34 |
114799 | ESCO1 | ATC1 | Human | Thyroid | ATC | 3.79e-06 | 2.41e-01 | 0.2878 |
Page: 1 2 3 4 5 6 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
GO:001820514 | Esophagus | ESCC | peptidyl-lysine modification | 259/8552 | 376/18723 | 3.90e-20 | 5.26e-18 | 259 |
GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
GO:001839413 | Esophagus | ESCC | peptidyl-lysine acetylation | 123/8552 | 169/18723 | 6.58e-13 | 2.94e-11 | 123 |
GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
GO:004354313 | Esophagus | ESCC | protein acylation | 165/8552 | 243/18723 | 1.69e-12 | 7.14e-11 | 165 |
GO:000647313 | Esophagus | ESCC | protein acetylation | 140/8552 | 201/18723 | 4.37e-12 | 1.69e-10 | 140 |
GO:00062754 | Esophagus | ESCC | regulation of DNA replication | 73/8552 | 107/18723 | 1.97e-06 | 2.28e-05 | 73 |
GO:00070627 | Esophagus | ESCC | sister chromatid cohesion | 40/8552 | 62/18723 | 2.14e-03 | 9.54e-03 | 40 |
GO:0018205 | Liver | NAFLD | peptidyl-lysine modification | 65/1882 | 376/18723 | 9.42e-06 | 3.02e-04 | 65 |
GO:0043543 | Liver | NAFLD | protein acylation | 43/1882 | 243/18723 | 1.70e-04 | 3.07e-03 | 43 |
GO:0006473 | Liver | NAFLD | protein acetylation | 37/1882 | 201/18723 | 2.10e-04 | 3.61e-03 | 37 |
GO:0018394 | Liver | NAFLD | peptidyl-lysine acetylation | 32/1882 | 169/18723 | 3.24e-04 | 5.00e-03 | 32 |
GO:00064731 | Liver | Cirrhotic | protein acetylation | 84/4634 | 201/18723 | 7.50e-08 | 2.25e-06 | 84 |
GO:00183941 | Liver | Cirrhotic | peptidyl-lysine acetylation | 73/4634 | 169/18723 | 1.08e-07 | 3.07e-06 | 73 |
GO:00435431 | Liver | Cirrhotic | protein acylation | 95/4634 | 243/18723 | 4.73e-07 | 1.07e-05 | 95 |
GO:00182051 | Liver | Cirrhotic | peptidyl-lysine modification | 134/4634 | 376/18723 | 1.29e-06 | 2.59e-05 | 134 |
GO:0000819 | Liver | Cirrhotic | sister chromatid segregation | 65/4634 | 202/18723 | 1.01e-02 | 4.52e-02 | 65 |
GO:00182052 | Liver | HCC | peptidyl-lysine modification | 230/7958 | 376/18723 | 1.51e-13 | 8.32e-12 | 230 |
Page: 1 2 3 4 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
hsa041104 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
hsa0411011 | Liver | Cirrhotic | Cell cycle | 61/2530 | 157/8465 | 9.53e-03 | 3.21e-02 | 1.98e-02 | 61 |
hsa041102 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa041103 | Liver | HCC | Cell cycle | 106/4020 | 157/8465 | 2.54e-07 | 3.04e-06 | 1.69e-06 | 106 |
hsa041108 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
hsa0411015 | Oral cavity | OSCC | Cell cycle | 118/3704 | 157/8465 | 7.15e-16 | 2.66e-14 | 1.35e-14 | 118 |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ESCO1 | SNV | Missense_Mutation | rs200657231 | c.1718N>A | p.Arg573Gln | p.R573Q | Q5FWF5 | protein_coding | tolerated(0.31) | benign(0) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ESCO1 | SNV | Missense_Mutation | c.928A>G | p.Ile310Val | p.I310V | Q5FWF5 | protein_coding | deleterious(0) | benign(0.277) | TCGA-BH-A0WA-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ESCO1 | SNV | Missense_Mutation | c.1699G>T | p.Asp567Tyr | p.D567Y | Q5FWF5 | protein_coding | deleterious(0) | benign(0.275) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ESCO1 | SNV | Missense_Mutation | novel | c.1847N>G | p.Ala616Gly | p.A616G | Q5FWF5 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-GM-A4E0-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | CR |
ESCO1 | insertion | Nonsense_Mutation | novel | c.2153_2154insCAGGAGTTTGAGACCAGCCTTGCCAACATTGTGA | p.Val719ArgfsTer11 | p.V719Rfs*11 | Q5FWF5 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
ESCO1 | insertion | Nonsense_Mutation | novel | c.2060_2061insAAACCTGTTCTCTACTGAAAATACAAAAATTAGCTGAG | p.Met688AsnfsTer12 | p.M688Nfs*12 | Q5FWF5 | protein_coding | TCGA-A8-A09X-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
ESCO1 | deletion | Frame_Shift_Del | novel | c.2151delN | p.Val718Ter | p.V718* | Q5FWF5 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
ESCO1 | SNV | Missense_Mutation | c.1688N>G | p.Ser563Cys | p.S563C | Q5FWF5 | protein_coding | deleterious(0) | possibly_damaging(0.707) | TCGA-EK-A2RA-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
ESCO1 | SNV | Missense_Mutation | novel | c.2128C>G | p.Leu710Val | p.L710V | Q5FWF5 | protein_coding | deleterious(0) | possibly_damaging(0.514) | TCGA-VS-A958-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ESCO1 | SNV | Missense_Mutation | c.1747N>T | p.His583Tyr | p.H583Y | Q5FWF5 | protein_coding | tolerated(0.42) | benign(0.035) | TCGA-AA-3697-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |